Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03035955 · ClinicalTrials.gov registry record · Phase 2
Azelaic Acid on Demodex Counts in Rosacea
A Phase 2 study, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03035955 is a Phase 2 study that has completed, run by Wake Forest University. The registered enrollment target is 20 participants.
The verdict
NCT03035955, a Phase 2 study, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the effects of azelaic acid on Demodex folliculorum counts and disease condition via a split face design in approximately twenty patients with mild to moderate rosacea. The investigators hypothesize that treatment of rosacea with azelaic acid will lead to a decreased Demodex folliculorum count as well as an improvement in lesion count and redness.
Interventions
- DRUG Azelaic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03035955
The ClinicalTrials.gov registry entry for NCT03035955 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azelaic acid is the first listed.
NCT03035955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03035955 about?
NCT03035955 is a clinical study titled "Azelaic Acid on Demodex Counts in Rosacea". The purpose of this study is to measure the effects of azelaic acid on Demodex folliculorum counts and disease condition via a split face design in approximately twenty patients with mild to moderate rosacea. The investigators hypothesize that treatment of rosacea with azelaic acid will lead to a de...
What is the current status of trial NCT03035955?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2010-12. Estimated completion is 2012-02-02.
What interventions are being tested in trial NCT03035955?
The interventions under investigation include: Azelaic acid (DRUG).
Who is sponsoring clinical trial NCT03035955?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.